| Literature DB >> 36179667 |
Eiko Hayase1, Tomo Hayase1, Mohamed A Jamal1, Takahiko Miyama1, Chia-Chi Chang1, Miriam R Ortega1, Saira S Ahmed1, Jennifer L Karmouch1, Christopher A Sanchez1, Alexandria N Brown1, Rawan K El-Himri1, Ivonne I Flores1, Lauren K McDaniel1, Dung Pham1, Taylor Halsey1, Annette C Frenk1, Valerie A Chapa1, Brooke E Heckel1, Yimei Jin1, Wen-Bin Tsai1, Rishika Prasad1, Lin Tan2, Lucas Veillon2, Nadim J Ajami1, Jennifer A Wargo1, Jessica Galloway-Peña3, Samuel Shelburne4, Roy F Chemaly5, Lauren Davey6, Robert W P Glowacki7, Chen Liu8, Gabriela Rondon9, Amin M Alousi9, Jeffrey J Molldrem9, Richard E Champlin9, Elizabeth J Shpall9, Raphael H Valdivia6, Eric C Martens7, Philip L Lorenzi2, Robert R Jenq10.
Abstract
The intestinal microbiota is an important modulator of graft-versus-host disease (GVHD), which often complicates allogeneic hematopoietic stem cell transplantation (allo-HSCT). Broad-spectrum antibiotics such as carbapenems increase the risk for intestinal GVHD, but mechanisms are not well understood. In this study, we found that treatment with meropenem, a commonly used carbapenem, aggravates colonic GVHD in mice via the expansion of Bacteroides thetaiotaomicron (BT). BT has a broad ability to degrade dietary polysaccharides and host mucin glycans. BT in meropenem-treated allogeneic mice demonstrated upregulated expression of enzymes involved in the degradation of mucin glycans. These mice also had thinning of the colonic mucus layer and decreased levels of xylose in colonic luminal contents. Interestingly, oral xylose supplementation significantly prevented thinning of the colonic mucus layer in meropenem-treated mice. Specific nutritional supplementation strategies, including xylose supplementation, may combat antibiotic-mediated microbiome injury to reduce the risk for intestinal GVHD in allo-HSCT patients.Entities:
Keywords: Bacteroides; Bacteroides thetaiotaomicron; allogeneic hematopoietic stem cell transplantation; broad-spectrum antibiotics; carbapenem; graft-versus-host disease; intestinal microbiome; mucus layer; mucus-degrading bacteria; xylose
Mesh:
Substances:
Year: 2022 PMID: 36179667 PMCID: PMC9542352 DOI: 10.1016/j.cell.2022.09.007
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850